Reviewing Dare Bioscience Inc. (DARE)’s and Odonate Therapeutics Inc. (NASDAQ:ODT)’s results

Both Dare Bioscience Inc. (NASDAQ:DARE) and Odonate Therapeutics Inc. (NASDAQ:ODT) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dare Bioscience Inc. N/A 0.00 12.13M -1.68 0.00
Odonate Therapeutics Inc. N/A 0.00 100.72M -4.10 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Dare Bioscience Inc. and Odonate Therapeutics Inc.


Table 2 provides Dare Bioscience Inc. and Odonate Therapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Dare Bioscience Inc. 0.00% -151% -137.4%
Odonate Therapeutics Inc. 0.00% -73.9% -65.8%


Dare Bioscience Inc. has a Current Ratio of 6.6 and a Quick Ratio of 6.6. Competitively, Odonate Therapeutics Inc.’s Current Ratio is 5.8 and has 5.8 Quick Ratio. Dare Bioscience Inc.’s better ability to pay short and long-term obligations than Odonate Therapeutics Inc.

Institutional and Insider Ownership

Roughly 7.7% of Dare Bioscience Inc. shares are held by institutional investors while 95.8% of Odonate Therapeutics Inc. are owned by institutional investors. About 0.8% of Dare Bioscience Inc.’s share are held by insiders. Competitively, insiders own roughly 2.4% of Odonate Therapeutics Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dare Bioscience Inc. -11.26% -14.64% 7.99% -4.05% -16.23% 26.15%
Odonate Therapeutics Inc. 7.87% -11.16% 32.46% 27.88% -3.65% 57.67%

For the past year Dare Bioscience Inc. has weaker performance than Odonate Therapeutics Inc.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.